Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 11 of 11 for “"Therapeutic Antibody"”.

  1. A Novel Syndecan-1 Targeted Therapeutic Antibody Inhibits Macropinocytosis and Induces Anti-Tumor Immunity in Pancreatic Cancer

    … and their role in PDAC development and growth, therapeutic strategies to quench KRAS*-driven malignant progression are urgently needed to improve the clinical outcome for this disease. Our previous work identified Syndecan-1 (SDC1), a highly expressed heparan sulfate proteoglycan, as a critical …

    uthsc Repository record for A Novel Syndecan-1 Targeted Therapeutic Antibody Inhibits Macropinocytosis and Induces Anti-Tumor Immunity in Pancreatic Cancer (opens in a new tab)

  2. CHARACTERIZATION OF DENGUE NEUTRALIZING ANTIBODIES USING RECOMBINANT ANTIBODIES TECHNOLOGY

    … LAID THE CORNERSTONES FOR SUBSEQUENT VACCINE AND THERAPEUTIC ANTIBODY DEVELOPMENT AS WELL AS FOR TODAY?S EXPLODING IMMUNOTHERAPY RESEARCH. THE FIRST HALF OF THIS THESIS IS DEDICATED TO THE CLONING, EXPRESSION, AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES OBTAINED FROM TWO NATURALLY INFECTED …

    nus Repository record for CHARACTERIZATION OF DENGUE NEUTRALIZING ANTIBODIES USING RECOMBINANT ANTIBODIES TECHNOLOGY (opens in a new tab)

  3. Ube4B Levels Determine The Efficacy of Egfr and Stat5 Inhibitors In Treatment Resistant Neuroblastoma

    … We observed that treatment with Cetuximab, a therapeutic antibody targeting the EGFR, significantly inhibited the proliferation of neuroblastoma cells depleted of UBE4B. Addition of a STAT5 inhibitor potentiated the Cetuximab-induced inhibition of proliferation, reduced migration, and enhanced …

    uthsc Repository record for Ube4B Levels Determine The Efficacy of Egfr and Stat5 Inhibitors In Treatment Resistant Neuroblastoma (opens in a new tab)

  4. Fine-tuning Boltz for Antibody-Antigen Binding Prediction

    Accurate prediction of antibody-antigen binding is a central challenge in computational immunology. Its direct implication for therapeutic antibody design and vaccine development has made it one of the most rapidly growing fields. Recent advances in protein language models and structure prediction …

    mit Repository record for Fine-tuning Boltz for Antibody-Antigen Binding Prediction (opens in a new tab)

  5. "Chasing a ghost": Addressing the opalescence/aggregation relationship of an IgG 1 antibody

    … aggregation/opalescence relationship of an IgG 1 therapeutic antibody under a variety of conditions. The opalescence characteristics of three antibodies, Mab 1, 2 and 3, were examined as a function of salt dependence, protein concentration and temperature, using a variety of biophysical …

    unh-thes Repository record for "Chasing a ghost": Addressing the opalescence/aggregation relationship of an IgG 1 antibody (opens in a new tab)

  6. Modulation of Immunity via Antibodies Displayed on in situ Forming Peptide Co-assemblies

    … region (Fc) for protein A/G (pAG). A therapeutic antibody can be displayed through non-covalent Fc-pAG interactions. Proof-of-concept studies demonstrate that antibodies were displayed via His-tags through the linker proteins, namely His-tag/αH6-IgG/pAG interactions. Displayed …

    duquesne Repository record for Modulation of Immunity via Antibodies Displayed on in situ Forming Peptide Co-assemblies (opens in a new tab)

  7. On Epitope-Paratope Interactions of Emerging to Endemic Viruses

    … antibodies that bind virus epitopes via the antibody’s paratope domain in an epitope-paratope interaction (EPI). EPIs are key aspects of the dynamic interplay between the virus and the host immune response to neutralize the virus. Studying EPIs enables us to better understand viral …

    mit Repository record for On Epitope-Paratope Interactions of Emerging to Endemic Viruses (opens in a new tab)

  8. Engineering aglycosylated antibody variants with immune effector functions

    … antibodies have emerged as a promising class of therapeutics for the treatment of human disease, and in particular human cancer. While multiple mechanisms contribute to antibody efficacy, the engagement and activation of immune effector cells - mediated by the interaction of the conserved Fc …

    mit Repository record for Engineering aglycosylated antibody variants with immune effector functions (opens in a new tab)

  9. Enhancing pharmaceutical formulations to improve efficacy and delivery of drug molecules

    … high-concentration protein suspensions for therapeutic antibody, in particular monoclonal antibody (MAb), delivery. (1) Influenza resistance to small molecule neuraminidase (NA) inhibitors is spreading. Little emphasis, however, has been placed on alternative formulations of inhibitors. We …

    mit Repository record for Enhancing pharmaceutical formulations to improve efficacy and delivery of drug molecules (opens in a new tab)

  10. VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS: DEVELOPMENT AND OPTIMIZATIONOF RELIABLE VIRAL CLEARANCE STRATEGIES

    … within downstream processing for monoclonal antibody (mAb) production, with the overarching goal of establishing procedures that are effective, reproducible, and fully transferable to the biopharmaceutical industry. During the first year, thanks to a structured training period at the …

    milano Repository record for VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS: DEVELOPMENT AND OPTIMIZATIONOF RELIABLE VIRAL CLEARANCE STRATEGIES (opens in a new tab)

  11. Human Antibody Response to Flaviviruses and SARS-Coronavirus-2

    … mechanisms and can help inform vaccine and therapeutic development. This thesis describes the characterization of the human antibody response to several important viral pathogens, all of which are either emerging pathogens posing significant public health burdens or are already responsible …

    rockefeller Repository record for Human Antibody Response to Flaviviruses and SARS-Coronavirus-2 (opens in a new tab)